Beyond the Pages: CCJM Podcast

Update on antiobesity medications in adults PART TWO

In this two-part podcast featuring the Cleveland Clinic Journal of Medicine article, “Update on antiobesity pharmacotherapy in adults: Current and emerging options,” Dr. Farah Ziyadeh, and Dr. Yael Mauer, Cleveland Clinic, join moderator Dr. Craig Nielsen, Cleveland Clinic. The trio discusses available antiobesity medications, including the incretin mimetics, and emerging antiobesity medications currently under investigation.

Update on antiobesity medications in adults PART ONE

In this two-part podcast featuring the Cleveland Clinic Journal of Medicine article, “Update on antiobesity pharmacotherapy in adults: Current and emerging options,” Dr. Farah Ziyadeh, and Dr. Yael Mauer, Cleveland Clinic, join moderator Dr. Craig Nielsen, Cleveland Clinic. The trio discusses available antiobesity medications, including the incretin mimetics, and emerging antiobesity medications currently under investigation.

Lipoprotein(a) in clinical practice

Listen as Dr. Astefanos Al-Dalakta and Dr. Ashish Sarraju, Cleveland Clinic, join moderator Dr. George Thomas, Cleveland Clinic, to discuss what clinicians need to know about lipoprotein(a) in clinical practice. Topics discussed include summarizes evidence on risk, screening strategies, and evolving therapies for elevated lipoprotein(a).

Testing for PFAS ‘forever chemicals’ PART TWO

This two-part podcast moderated by Dr. Adam Brown, Cleveland Clinic, features a discussion with Philip Zuccaro, BS, and Vasilis Vasiliou, PhD, both of the Yale School of Public Health, on the Cleveland Clinic Journal of Medicine 1-minute consult article, “Does my patient need testing for PFAS ‘forever chemicals’?”

Testing for PFAS ‘forever chemicals’ PART ONE

This two-part podcast moderated by Dr. Adam Brown, Cleveland Clinic, features a discussion with Philip Zuccaro, BS, and Vasilis Vasiliou, PhD, both of the Yale School of Public Health, on the Cleveland Clinic Journal of Medicine 1-minute consult article, “Does my patient need testing for PFAS ‘forever chemicals’?”